Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
For full access to this article login to GEN Select now.
Protein Arrays as Key Discovery Tools
Increasing Number of Firms Explore This Route to Find Novel Drug Candidates
- Drug development is such a formidable challenge that, some believe, it can only be undertaken effectively by big pharma. Time-consuming and expensive, the classic approach has been to screen vast numbers of low molecular weight compounds for efficacy in blocking disease processes and then move through various levels of ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.